• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫治疗时代突变抗原的鉴定与临床应用

The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.

作者信息

Kye Yae, Nagineni Lokesh, Gadad Shrikanth, Ramirez Fabiola, Riva Hannah, Fernandez Lorena, Samaniego Michelle, Holland Nathan, Yeh Rose, Takigawa Kei, Dhandayuthapani Subramanian, Chacon Jessica

机构信息

Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

L. Frederick Francis Graduate School of Biomedical Sciences, Texas Tech University Health Sciences Center El Paso, El Paso, TX 79905, USA.

出版信息

Cancers (Basel). 2022 Aug 31;14(17):4255. doi: 10.3390/cancers14174255.

DOI:10.3390/cancers14174255
PMID:36077792
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9454936/
Abstract

The era of personalized cancer therapy is here. Advances in the field of immunotherapy have paved the way for the development of individualized neoantigen-based therapies that can translate into favorable treatment outcomes and fewer side effects for patients. Addressing challenges related to the identification, access, and clinical application of neoantigens is critical to accelerating the development of individualized immunotherapy for cancer patients.

摘要

个性化癌症治疗的时代已经到来。免疫治疗领域的进展为基于个性化新抗原的疗法的发展铺平了道路，这类疗法能够为患者带来良好的治疗效果并减少副作用。应对与新抗原的识别、获取及临床应用相关的挑战，对于加速为癌症患者开发个性化免疫疗法至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/aa2badde969a/cancers-14-04255-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/388cc91249c7/cancers-14-04255-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/a8c6befd0d72/cancers-14-04255-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/aa2badde969a/cancers-14-04255-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/388cc91249c7/cancers-14-04255-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/a8c6befd0d72/cancers-14-04255-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb4a/9454936/aa2badde969a/cancers-14-04255-g003.jpg

相似文献

1
The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy.免疫治疗时代突变抗原的鉴定与临床应用
Cancers (Basel). 2022 Aug 31;14(17):4255. doi: 10.3390/cancers14174255.
2
Engineering neoantigen vaccines to improve cancer personalized immunotherapy.工程化 neoantigen 疫苗以改善癌症个体化免疫治疗。
Int J Biol Sci. 2022 Sep 1;18(15):5607-5623. doi: 10.7150/ijbs.76281. eCollection 2022.
3
Individualized Neoantigen-Directed Melanoma Therapy.个体化新抗原导向的黑色素瘤治疗
Am J Clin Dermatol. 2025 Mar;26(2):225-235. doi: 10.1007/s40257-025-00920-4. Epub 2025 Jan 29.
4
Targeting neoantigens for cancer immunotherapy.针对新抗原的癌症免疫疗法。
Biomark Res. 2021 Jul 28;9(1):61. doi: 10.1186/s40364-021-00315-7.
5
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?新抗原靶向——癌症免疫治疗新时代的曙光？
Front Immunol. 2017 Dec 19;8:1848. doi: 10.3389/fimmu.2017.01848. eCollection 2017.
6
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.新抗原鉴定策略使难治性实体瘤的个体化免疫治疗成为可能。
J Clin Invest. 2019 Mar 5;129(5):2056-2070. doi: 10.1172/JCI99538. Print 2019 May 1.
7
Prospects and challenges of neoantigen applications in oncology.肿瘤学中新抗原应用的前景与挑战。
Int Immunopharmacol. 2024 Dec 25;143(Pt 1):113329. doi: 10.1016/j.intimp.2024.113329. Epub 2024 Oct 14.
8
Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.特异性肿瘤进化及其对个体化癌症免疫治疗中新抗原靶向和生物标志物的影响。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-003001.
9
The role of neoantigens in tumor immunotherapy.肿瘤免疫治疗中的新抗原作用。
Biomed Pharmacother. 2022 Jul;151:113118. doi: 10.1016/j.biopha.2022.113118. Epub 2022 May 24.
10
Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens.具有个体化和共享新抗原的治疗性癌症疫苗的研发与临床应用
Vaccines (Basel). 2024 Jun 27;12(7):717. doi: 10.3390/vaccines12070717.

引用本文的文献

1
Advances and Challenges in Immunotherapy for Metastatic Uveal Melanoma: Clinical Strategies and Emerging Targets.转移性葡萄膜黑色素瘤免疫治疗的进展与挑战：临床策略与新兴靶点
J Clin Med. 2025 Jul 19;14(14):5137. doi: 10.3390/jcm14145137.
2
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects.肺癌中基于新抗原的免疫疗法：进展、挑战与前景
Cancers (Basel). 2025 Jun 12;17(12):1953. doi: 10.3390/cancers17121953.
3
Tumor neoantigens and tumor immunotherapies.肿瘤新抗原与肿瘤免疫疗法。

本文引用的文献

1
Neoantigens in precision cancer immunotherapy: from identification to clinical applications.精准肿瘤免疫治疗中的新抗原：从鉴定到临床应用。
Chin Med J (Engl). 2022 Jun 5;135(11):1285-1298. doi: 10.1097/CM9.0000000000002181.
2
Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA-I proteins.通过预测 HLA-I 蛋白对候选肽的呈递来为癌症疫苗确定优先肽。
Biometrics. 2023 Sep;79(3):2664-2676. doi: 10.1111/biom.13717. Epub 2022 Jul 29.
3
Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
Aging Med (Milton). 2024 Apr 12;7(2):224-230. doi: 10.1002/agm2.12295. eCollection 2024 Apr.
种族和民族对固体肿瘤患者使用下一代测序的趋势，在医疗保险国家覆盖范围确定实施后的变化。
JAMA Netw Open. 2021 Dec 1;4(12):e2138219. doi: 10.1001/jamanetworkopen.2021.38219.
4
Targeting public neoantigens for cancer immunotherapy.靶向公共新抗原用于癌症免疫治疗。
Nat Cancer. 2021 May;2(5):487-497. doi: 10.1038/s43018-021-00210-y. Epub 2021 May 17.
5
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors.基于 T 细胞受体的治疗：实体瘤的创新治疗方法。
J Hematol Oncol. 2021 Jun 30;14(1):102. doi: 10.1186/s13045-021-01115-0.
6
Neoantigen landscape in metastatic nasopharyngeal carcinoma.转移性鼻咽癌中的新抗原图谱
Theranostics. 2021 Apr 19;11(13):6427-6444. doi: 10.7150/thno.53229. eCollection 2021.
7
Resident memory T cells in tumor-distant tissues fortify against metastasis formation.肿瘤远处组织中的驻留记忆 T 细胞可加强对转移形成的防御。
Cell Rep. 2021 May 11;35(6):109118. doi: 10.1016/j.celrep.2021.109118.
8
Neoantigen: A New Breakthrough in Tumor Immunotherapy.肿瘤免疫治疗新突破：新抗原
Front Immunol. 2021 Apr 16;12:672356. doi: 10.3389/fimmu.2021.672356. eCollection 2021.
9
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins.针对细胞内蛋白的T细胞受体模拟（TCRm）抗体疗法。
Antib Ther. 2019 Jan 21;2(1):22-32. doi: 10.1093/abt/tbz001. eCollection 2019 Jan.
10
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.免疫检查点抑制剂引发的迟发性和持久性免疫相关不良事件：免疫治疗中一个被忽视的方面。
Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14.